RepliCel Life Sciences Inc (REPCF)
0.0428
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
RepliCel Life Sciences EPS Diluted (Quarterly): -0.0075 for Sept. 30, 2023
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -0.0075 |
| June 30, 2023 | -0.0074 |
| March 31, 2023 | -0.0074 |
| December 31, 2022 | 0.0221 |
| September 30, 2022 | -0.023 |
| June 30, 2022 | -0.0235 |
| March 31, 2022 | -0.0158 |
| December 31, 2021 | -0.0238 |
| September 30, 2021 | -0.0238 |
| June 30, 2021 | -0.0244 |
| March 31, 2021 | -0.0316 |
| December 31, 2020 | -0.0077 |
| September 30, 2020 | -0.015 |
| June 30, 2020 | -0.0072 |
| March 31, 2020 | -0.0075 |
| December 31, 2019 | -0.0303 |
| September 30, 2019 | -0.0151 |
| June 30, 2019 | -0.0224 |
| March 31, 2019 | -0.0226 |
| December 31, 2018 | -0.0302 |
| September 30, 2018 | -0.0306 |
| June 30, 2018 | -0.0232 |
| March 31, 2018 | -0.0238 |
| December 31, 2017 | -0.0157 |
| September 30, 2017 | -0.0479 |
| Date | Value |
|---|---|
| June 30, 2017 | -0.1041 |
| March 31, 2017 | -0.0755 |
| December 31, 2016 | -0.0848 |
| September 30, 2016 | -0.0767 |
| June 30, 2016 | -0.0931 |
| March 31, 2016 | -0.1239 |
| December 31, 2015 | -0.1647 |
| September 30, 2015 | -0.1452 |
| June 30, 2015 | -0.2033 |
| March 31, 2015 | -0.1615 |
| December 31, 2014 | -0.1935 |
| September 30, 2014 | -0.1837 |
| June 30, 2014 | -0.275 |
| March 31, 2014 | -0.2721 |
| December 31, 2013 | -0.2062 |
| September 30, 2013 | 0.5776 |
| June 30, 2013 | -0.1955 |
| March 31, 2013 | -0.1985 |
| December 31, 2012 | -0.2017 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.3961 |
| March 31, 2012 | -0.1997 |
| December 31, 2011 | -1.758 |
| September 30, 2011 | 0.2043 |
| June 30, 2011 | -0.31 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.0316
Minimum
Mar 2021
0.0221
Maximum
Dec 2022
-0.0151
Average
-0.0155
Median
EPS Diluted (Quarterly) Benchmarks
| Acasti Pharma Inc | -0.0542 |
| Aurinia Pharmaceuticals Inc | -0.18 |
| Edesa Biotech Inc | -0.54 |
| Lexaria Bioscience Corp | -0.06 |
| InMed Pharmaceuticals Inc | -0.19 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.61M |
| Revenue (Quarterly) | 0.0659M |
| Total Expenses (Quarterly) | 0.3084M |
| Enterprise Value | 2.791M |
| Profit Margin (Quarterly) | -925.7% |
| Earnings Yield | -0.44% |
| Normalized Earnings Yield | 23.15 |